These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

118 related articles for article (PubMed ID: 7169959)

  • 1. Absence of systemic hormonal effects in an oestradiol diether topically active on the vaginal mucosa.
    Wolff JP; Cachelou R; Guéritée N
    Maturitas; 1982 Dec; 4(4):239-46. PubMed ID: 7169959
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effects of orally administered oestradiol decanoate on plasma oestradiol, oestrone and gonadotrophin levels, vaginal cytology, cervical mucus and endometrium in ovariectomized women.
    Kicovic PM; Luisi M; Franchi F; Alicicco E
    Clin Endocrinol (Oxf); 1977 Jul; 7(1):73-7. PubMed ID: 880735
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Urogenital disorders associated with oestrogen deficiency: the role of promestriene as topical oestrogen therapy.
    Santos I; Clissold S
    Gynecol Endocrinol; 2010 Sep; 26(9):644-51. PubMed ID: 20374067
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Oestrogen concentrations in plasma, endometrium, myometrium and vagina of postmenopausal women, and effects of vaginal oestriol (E3) and oestradiol (E2) applications.
    van Haaften M; Donker GH; Haspels AA; Thijssen JH
    J Steroid Biochem; 1989 Oct; 33(4A):647-53. PubMed ID: 2811377
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Safety of promestriene capsule used in postmenopausal atrophic vaginitis].
    Sun AJ; Lin SQ; Jing LH; Wang ZY; Ye JL; Zhang Y
    Zhonghua Fu Chan Ke Za Zhi; 2009 Aug; 44(8):593-6. PubMed ID: 20003787
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of orally administered oestrogens on circulating oestrogen profiles in post-menopausal women.
    Aedo AR; Sundén M; Landgren BM; Diczfalusy E
    Maturitas; 1989 Jun; 11(2):159-68. PubMed ID: 2547139
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Oestrogens, gonadotropins and prolactin after intra-vaginal administration of oestriol in post-menopausal women.
    Keller PJ; Riedmann R; Fischer M; Gerber C
    Maturitas; 1981 Mar; 3(1):47-53. PubMed ID: 6789033
    [TBL] [Abstract][Full Text] [Related]  

  • 8. An oestrone-releasing vaginal ring in the treatment of climacteric women.
    Sipinen S; Lähteenmäki P; Luukkainen T
    Maturitas; 1980 Dec; 2(4):291-9. PubMed ID: 7231201
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Endometrial and vaginal response to three different oestrogen preparations administered by the transdermal and oral routes.
    Johannisson E; Landgren BM; Diczfalusy E
    Maturitas; 1988 Oct; 10(3):181-92. PubMed ID: 3185292
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of one-month treatment with vaginal promestriene on serum estrone sulfate levels in cancer patients: a pilot study.
    Del Pup L; Postruznik D; Corona G
    Maturitas; 2012 May; 72(1):93-4. PubMed ID: 22349253
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacokinetics and pharmacodynamic effects of vaginal oestradiol administration from silastic rings in post-menopausal women.
    Englund DE; Victor A; Johansson ED
    Maturitas; 1981 Aug; 3(2):125-33. PubMed ID: 6793811
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effects of intravaginal oestrogen treatment upon the vaginal absorption of conjugated equine oestrogens.
    Carlström K; Karlgren E; Furuhjelm M; Ryd-Kjellén E
    Maturitas; 1982 Dec; 4(4):277-83. PubMed ID: 6302443
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Study of estrogenic effects of promestriene].
    Gaudefroy M; Pigache JP
    Arch Anat Cytol Pathol; 1977; 25(2):125-8. PubMed ID: 332094
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Estrogens--pharmacokinetics and pharmacodynamics with special reference to vaginal administration and the new estradiol formulation--Estring.
    Johnston A
    Acta Obstet Gynecol Scand Suppl; 1996; 163():16-25. PubMed ID: 8916471
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Topical hormonal treatment and urogenital atrophy].
    Sitruk-Ware R; Thomas JL
    Praxis (Bern 1994); 1997 Aug; 86(33):1245-8. PubMed ID: 9381009
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparative pharmacokinetics of oestradiol, oestrone, oestrone sulfate and "conjugated oestrogens" after oral administration.
    Schindler AE; Bolt HM; Zwirner M; Hochlehnert G; Göser R
    Arzneimittelforschung; 1982; 32(7):787-91. PubMed ID: 6289846
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmacokinetics and biotransformation of orally administered oestrone sulphate and oestradiol valerate in post-menopausal women.
    Aedo AR; Landgren BM; Diczfalusy E
    Maturitas; 1990 Nov; 12(4):333-43. PubMed ID: 2124648
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Low-dose oestradiol in the treatment of urogenital oestrogen deficiency--a pharmacokinetic and pharmacodynamic study.
    Nilsson K; Heimer G
    Maturitas; 1992 Oct; 15(2):121-7. PubMed ID: 1470044
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effects of RU16117, an orally active weak oestrogenic compound, in postmenopausal women.
    Faure N; Labrie F; Olivier G; Tremblay M; Cloutier D; Lemay A; Ferland L; Azadian-Boulanger G; Bouton MM; Husson JM; Raynaud JP
    Maturitas; 1980 Jul; 2(2):155-68. PubMed ID: 6782429
    [TBL] [Abstract][Full Text] [Related]  

  • 20. An intrauterine progesterone contraceptive system (52 mg) used in pre- and peri-menopausal patients with endometrial hyperplasia.
    Volpe A; Botticelli A; Abrate M; Dalla Vecchia E; Mantovani M; Carani C; Grasso A; Mazza V; Di Renzo GC
    Maturitas; 1982 Apr; 4(1):73-9. PubMed ID: 6285154
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.